6-K filed Jul 20, 2026 at 07:00 ET
Kamada announced a three-year agreement to supply normal source plasma from its Texas collection centers to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue over three years. Initial commercial sales are expected in Q4 2026, and this agreement validates the company's investment in its U.S. plasma collection operations, supporting its vertical-integration strategy and multi-year revenue growth objectives. The agreement is included in the company's current annual guidance, which projects total revenues of $200-$205 million and adjusted EBITDA of $50-$53 million for fiscal year 2026.